Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15382189 | 0.86 | VNN1 (0.41) | HTR2AHTR2CHTR2BVNN1CCR5 | |
| SCHEMBL21946381 | 0.83 | HTR2B (0.39) | HTR2AHTR2CHTR2BVNN1CCR5 | |
| SCHEMBL19370311 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BEIF2AK4 | |
| SCHEMBL19370310 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BEIF2AK4 | |
| SCHEMBL799513 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BEIF2AK4 | |
| SCHEMBL21103552 | 0.79 | EIF2AK4 (0.35) | EIF2AK4VNN1 | |
| SCHEMBL27420770 | 0.78 | SOS1 (0.35) | EIF2AK4VNN1CCR5SOS1 | |
| SCHEMBL19700368 | 0.78 | VNN1 (0.37) | EIF2AK4VNN1 | |
| SCHEMBL18390547 | 0.74 | CCR5 (0.40) | VNN1CCR5 | |
| SCHEMBL31622163 | 0.73 | VNN1 (0.38) | EIF2AK4VNN1SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | HTR2A 4537/4885HTR2C 4564/4885HTR2B 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.